Publications by authors named "E Scarr"

Article Synopsis
  • The study investigates the differences in receptor binding in the brains of people with schizophrenia, specifically focusing on the Muscarinic Receptor Deficit subgroup (MRDS), which shows reduced binding to the M1 receptor.
  • Researchers confirmed MRDS by measuring [H]pirenzepine binding and then examined the binding of other glutamate receptors ([H]kainate, [H]AMPA, [H]NMDA) in Brodmann's areas 9 and 10 to see if there were subgroup-specific differences.
  • Results showed that while M1 and kainate receptor binding was lower in BA 9 and BA 10 for MRDS individuals, other glutamate receptors (AMPA and NMDA) did not
View Article and Find Full Text PDF

Objectives: This study sought to identify pathways affected by rat cortical RNA that were changed after treatment with fluoxetine or imipramine.

Methods: We measured levels of cortical RNA in male rats using GeneChip Rat Exon 1.0 ST Array after treatment with vehicle (0.

View Article and Find Full Text PDF
Article Synopsis
  • - A study identified a subset of individuals with schizophrenia, referred to as muscarinic receptor deficit schizophrenia (MRDS), who exhibit significantly lower levels of cortical muscarinic M1 receptors compared to others with schizophrenia.
  • - Researchers analyzed gene expression data and found disturbances in a biochemical pathway associated with the processing of the β-amyloid precursor protein (APP), which led them to measure levels of APP-related proteins in the frontal cortex of MRDS and non-MRDS subjects.
  • - The results indicated that while those with MRDS had notably low muscarinic receptor levels, individuals with schizophrenia overall had lower levels of soluble APP (sAPP) compared to control subjects, suggesting that APP might play a role in the underlying mechanisms
View Article and Find Full Text PDF

Objectives: We have postulated that common changes in gene expression after treatment with different therapeutic classes of psychotropic drugs contribute to their common therapeutic mechanisms of action.

Methods: To test this hypothesis, we measured levels of cortical coding and non-coding RNA using GeneChip Rat Exon 1.0 ST Array after treatment with vehicle (chow only), chow containing 1.

View Article and Find Full Text PDF